Women with polycystic ovarian syndrome (PCOS) seeking fertility treatments face a trade-off between increased miscarriage risks and reduced chances of ovarian hyperstimulation syndrome (OHSS). A recent Cochrane review evaluates the efficacy and safety of in vitro maturation (IVM) compared to conventional in vitro fertilization (IVF) methods in this demographic.
Study Assessments and Methodology
The review analyzed four randomized controlled trials encompassing 810 participants undergoing assisted reproductive technology. Two of these studies were previously included and presented high bias risks, while two new studies demonstrated low bias risks, enhancing the reliability of the findings. Researchers focused on primary outcomes such as live birth rates and miscarriage incidences, utilizing statistical models to interpret the data.
Key Findings and Implications
IVM techniques did not significantly improve live birth rates compared to standard IVF when using a GnRH antagonist protocol, with an odds ratio suggesting uncertain benefits. However, the risk of miscarriage per clinical pregnancy increased notably with IVM. On the upside, IVM substantially reduced the incidence of moderate to severe OHSS, a serious complication associated with fertility treatments.
- IVM may lower live birth chances, ranging from 12.5% to 52.6% compared to standard IVF’s 45.7%.
- Miscarriage rates with IVM could escalate to 40.4%, double the 20.1% seen with IVF.
- OHSS incidence drops to between 0% and 2.4% with IVM, from 3.5% with conventional IVF.
Additionally, the risk of preterm birth and congenital anomalies showed little to no difference between the two methods, although data on congenital anomalies remained inconclusive. The findings highlight the need for further high-quality research to solidify these preliminary results and guide clinical decisions.
Choosing between IVM and conventional IVF involves weighing the lower risk of OHSS against the increased likelihood of miscarriage and uncertain live birth outcomes. For women with PCOS, the reduced risk of OHSS presents a significant benefit, potentially enhancing the safety of fertility treatments. However, the heightened miscarriage rates warrant careful consideration and consultation with healthcare providers.
Future advancements in IVM techniques, such as capacitation IVM systems, may offer improved outcomes by enhancing oocyte developmental competence. Ongoing trials are expected to provide more definitive evidence, which could refine fertility treatment protocols for women with PCOS. Patients and clinicians must stay informed about emerging research to make the best-informed decisions tailored to individual health profiles and fertility goals.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
